Breast Cancer

News in brief: Dual immunotherapy in early NSCLC; Menopausal symptoms in breast cancer survivors; Thrombotic events with CDK 4/6 inhibitors

Dual immunotherapy shows promise in early stage NSCLC The first randomised study to report on the role of neoadjuvant combination checkpoint inhibitors for operable, early stage non-small cell lung cancer (NSCLC) has shown promising results for nivolumab plus ipilimumab. Results from the NEOSTAR phase 2 trial published in Nature Medicine showed that combined neoadjuvant therapy ...

Already a member?

Login to keep reading.

© 2022 the limbic